Sanofi reported first‑quarter revenue of €10.51 billion, exceeding the €10.22 billion analyst consensus for the period ending March 31, 2026 calendar.
Business operating income reached €2.97 billion, ahead of the €2.85 billion forecast, reflecting solid performance in the first quarter despite rising expenses.
Dupixent sales surged 30.8% on a constant‑currency basis to €4.17 billion, comfortably beating the €3.89 billion estimate for the quarter.
Earnings per share rose 14% to €1.88, and Sanofi shares gained about 2% in early Paris trading by 07:20 GMT.